Role of DTIC (NSC 45388) in the chemotherapy of sarcomas

J. A. Gottlieb; R. S. Benjamin; L. H. Baker; R. M. O'Bryan; J. G. Sinkovics; B. Hoogstraten; J. M. Quagliana; S. E. Rivkin; G. P. Bodey; V. Rodriguez; G. R. Blumenschein; J. H. Saiki; C. Coltman; M. A. Burgess; P. Sullivan; T. Thigpen; R. Bottomley; S. Balcerzak; T. E. Moon

Role of DTIC (NSC 45388) in the chemotherapy of sarcomas

J. A. Gottlieb, R. S. Benjamin, L. H. Baker, R. M. O'Bryan, J. G. Sinkovics, B. Hoogstraten, J. M. Quagliana, S. E. Rivkin, G. P. Bodey, V. Rodriguez, G. R. Blumenschein, J. H. Saiki, C. Coltman, M. A. Burgess, P. Sullivan, T. Thigpen, R. Bottomley, S. Balcerzak, T. E. Moon

Sarcoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

142 Scopus citations

Abstract

DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition o DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.

Original language	English (US)
Pages (from-to)	199-203
Number of pages	5
Journal	CANCER TREAT.REP.
Volume	60
Issue number	2
State	Published - 1976

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Gottlieb, J. A., Benjamin, R. S., Baker, L. H., O'Bryan, R. M., Sinkovics, J. G., Hoogstraten, B., Quagliana, J. M., Rivkin, S. E., Bodey, G. P., Rodriguez, V., Blumenschein, G. R., Saiki, J. H., Coltman, C., Burgess, M. A., Sullivan, P., Thigpen, T., Bottomley, R., Balcerzak, S., & Moon, T. E. (1976). Role of DTIC (NSC 45388) in the chemotherapy of sarcomas. CANCER TREAT.REP., 60(2), 199-203.

@article{af3e869e297246a3bb8ad751482be69e,

title = "Role of DTIC (NSC 45388) in the chemotherapy of sarcomas",

abstract = "DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition o DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.",

author = "Gottlieb, {J. A.} and Benjamin, {R. S.} and Baker, {L. H.} and O'Bryan, {R. M.} and Sinkovics, {J. G.} and B. Hoogstraten and Quagliana, {J. M.} and Rivkin, {S. E.} and Bodey, {G. P.} and V. Rodriguez and Blumenschein, {G. R.} and Saiki, {J. H.} and C. Coltman and Burgess, {M. A.} and P. Sullivan and T. Thigpen and R. Bottomley and S. Balcerzak and Moon, {T. E.}",

year = "1976",

language = "English (US)",

volume = "60",

pages = "199--203",

journal = "CANCER TREAT.REP.",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Role of DTIC (NSC 45388) in the chemotherapy of sarcomas

AU - Gottlieb, J. A.

AU - Benjamin, R. S.

AU - Baker, L. H.

AU - O'Bryan, R. M.

AU - Sinkovics, J. G.

AU - Hoogstraten, B.

AU - Quagliana, J. M.

AU - Rivkin, S. E.

AU - Bodey, G. P.

AU - Rodriguez, V.

AU - Blumenschein, G. R.

AU - Saiki, J. H.

AU - Coltman, C.

AU - Burgess, M. A.

AU - Sullivan, P.

AU - Thigpen, T.

AU - Bottomley, R.

AU - Balcerzak, S.

AU - Moon, T. E.

PY - 1976

Y1 - 1976

N2 - DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition o DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.

AB - DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition o DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.

UR - http://www.scopus.com/inward/record.url?scp=0017159792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017159792&partnerID=8YFLogxK

M3 - Article

C2 - 769974

AN - SCOPUS:0017159792

SN - 0027-8874

VL - 60

SP - 199

EP - 203

JO - CANCER TREAT.REP.

JF - CANCER TREAT.REP.

IS - 2

ER -

Role of DTIC (NSC 45388) in the chemotherapy of sarcomas

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this